Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome

Huang, Hong; Shariat, Shahrokh F.; Sun, Tung‐Tien; Lepor, Herbert; Shapiro, Ellen; Hsieh, Jer Tsong; Ashfaq, Raheela; Lotan, Yair; Wu, Xue-Ru

doi:10.1016/j.humpath.2007.04.003

Cited by 73 publications

(62 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell Culture and Transfection-Human UMUC3 and RT112 bladder cancer cell lines were obtained from Dr. Xue-Ru Wu (Departments of Urology and Pathology, New York University School of Medicine) (12), and T24T was kindly provided by Dr. Dan Theodorescu (13). These cell lines were maintained at 37°C in a 5% CO 2 (14), and HCT116 XIAP Ϫ/Ϫ (HA-XIAP) transfection was stably established by transfection with HA-XIAP as described in our previous studies (7).…”

Section: Methodsmentioning

confidence: 99%

The Chinese Herb Isolate Isorhapontigenin Induces Apoptosis in Human Cancer Cells by Down-regulating Overexpression of Antiapoptotic Protein XIAP

Fang

Hou

et al. 2012

Journal of Biological Chemistry

Self Cite

View full text Add to dashboard Cite

Background:The anti-cancer activity and mechanisms of isorhapontigenin (ISO) have never been explored. Results: ISO exhibited an anti-cancer activity accompanied by apoptotic induction and XIAP down-regulation through attenuation of SP1 expression. Conclusion: ISO is an active anti-cancer compound by inducing apoptosis via down-regulation of SP1/XIAP pathway. Significance: Current studies identify a new promising active compound for therapy of human cancers with XIAP overexpression.

show abstract

Section: Methodsmentioning

confidence: 99%

The Chinese Herb Isolate Isorhapontigenin Induces Apoptosis in Human Cancer Cells by Down-regulating Overexpression of Antiapoptotic Protein XIAP

Fang

Hou

et al. 2012

Journal of Biological Chemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Uroplakin plays a key role in urothelial functions, including participation in the permeability barrier, adjustment of urothelial surface area, stabilization of the urothelial surface and development of the urinary tract (Huang et al, 2007). Owing to their specific expression in the urothelium, uroplakin has been investigated as a potential immunohistochemical markers for the primary lesions and the identification of the primary cancer in patients with metastases of unknown origin (Xu et al, 2001).…”

mentioning

confidence: 99%

High Expression Level of Preoperative Serum Uroplakin III is Associated with Biologically Aggressive Bladder Cancer

Tsumura

Matsumoto²,

Ikeda³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Uroplakins have been widely investigated as potential markers in patients with bladder cancer because these proteins are specific to the urothelium. However, the role of uroplakin proteins in bladder cancer remains unknown. In this study, preoperative serum levels of uroplakin III were measured in patients with urothelial carcinoma of the urinary bladder and examined for possible association with clinicopathological features and clinical outcomes. Materials and Methods: This study included 52 bladder cancer patients at various stages and 28 healthy controls. Uroplakin III levels were detected in preoperative sera using an automated dot blot system and a micro-dot blot array. Results: There was a significant increase in serum uroplakin III levels in patients with bladder cancer as compared to healthy controls (p<0.05). In addition, serum uroplakin III levels were associated with muscle-invasive status, high grade and lymphovascular invasion (p<0.02). Log-rank tests indicated high serum uroplakin III to be significantly associated with cancer-specific mortality. Conclusions: Determination of serum uroplakin III level could be valuable for identifying patients with biologically aggressive bladder cancer.

show abstract

“…One study employed a pan-UP antibody, which reacted with UPIb, UPII, and UPIII isoforms, to demonstrate the persistent expression of UP in advanced UC; however, the specific UPII protein level could not be determined using that pan-UP antibody. 11 Little is known about the protein expression of UPII in UC, possibly because of the absence of a specific UPII antibody.…”

mentioning

confidence: 99%

A Newly Developed Uroplakin II Antibody With Increased Sensitivity in Urothelial Carcinoma of the Bladder

Hoang

Tacha

et al. 2014

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Uroplakin II is a 15-kDa protein component of the urothelial plaques that enhance the permeability barrier and strength of the urothelium. Studies have shown uroplakin II messenger RNA to be expressed in bladder cancer tissues and peripheral blood of patients with urothelial carcinoma. Little is known about the protein expression of uroplakin II in urothelial carcinoma, possibly because of the absence of a commercially available uroplakin II antibody. Pathologists have used the uroplakin III antibody (AU1) to identify tumors of urothelial origin; however, the use of AU1 is limited because of its poor sensitivity.Objectives.-To evaluate a newly developed mouse monoclonal uroplakin II antibody (BC21) in urothelial carcinoma and to compare it with previously developed mouse monoclonal uroplakin III (BC17 and AU1).Design.-Uroplakin II and III antibodies were optimized for staining using a horseradish peroxidase-polymer detection system and were visualized with 3,3 0 -diaminobenzidine.Results.-BC21, BC17, and AU1 demonstrated sensitivities in urothelial carcinoma of the bladder of 79% (44 of 56), 55% (31 of 56) (P ¼ .002), and 34% (19 of 56) (P , .001), respectively. Subsequently, the increased staining sensitivity and intensity of BC21, compared with BC17, was validated in a larger study (134 of 174; 77% and 94 of 174; 54%, respectively) (P , .001). BC21 was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostatic and renal carcinomas.Conclusions. 1 This cancer is particularly associated with high recurrence and progression rates. About 70% of patients with superficial bladder cancer will experience tumor recurrence, and 10% to 15% of that subpopulation will eventually progress to muscle invasion. 2Early diagnosis, when the disease is still at a localized stage, increases the chance of successful treatment. The survival rate for in situ urinary bladder cancer is 97%. Tissue-based biomarkers for early diagnosis of bladder cancer are a major clinical need. Urothelial carcinoma (UC) originates in the urothelium and accounts for more than 90% to 95% of all bladder tumors. Adenocarcinoma and squamous cell carcinoma make up about 1% and 5%, respectively, of bladder carcinomas. Biomarkers expressed in the urothelium, such as uroplakins, could be valuable markers of UC of the bladder. Pathologists have used uroplakin (UP) III (clone AU1) to establish the urothelial origin of the tumor; however, the use of AU1 has been limited because of its poor sensitivity.The asymmetric-unit membrane plaques of the urothelium maintain the blood-urine barrier and prevent cells from rupturing during bladder distention. The molecular constituents of those plaques comprise four transmembrane UP isoforms: UPIa, UPIb, UPII, and UPIII, which are specific differentiation products of the urothelial cells. The UPII is a 15-kDa protein component of the urothelial plaques that enhance the permeability barrier and strength of the urothelium. 4 The expression of UPII is aberrant in urothelial car...

show abstract

Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome

Cited by 73 publications

References 34 publications

The Chinese Herb Isolate Isorhapontigenin Induces Apoptosis in Human Cancer Cells by Down-regulating Overexpression of Antiapoptotic Protein XIAP

The Chinese Herb Isolate Isorhapontigenin Induces Apoptosis in Human Cancer Cells by Down-regulating Overexpression of Antiapoptotic Protein XIAP

High Expression Level of Preoperative Serum Uroplakin III is Associated with Biologically Aggressive Bladder Cancer

A Newly Developed Uroplakin II Antibody With Increased Sensitivity in Urothelial Carcinoma of the Bladder

Contact Info

Product

Resources

About